Press release archive

Faron initiates phase I/II clinical trial in UK: Jun 11, 2008—The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Faron’s clinical trial application (CTA) for acute lung injury (ALI).; Download press release (PDF)
Jurilab announced the appointment of Carl T. Foster as the company’s new Chief Executive Officer: Apr 25, 2008; Download press release (PDF)
Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification: Mar 12, 2008—Prove-it Herpes offers considerable cost savings for healthcare industry by identifying eight herpesviruses simultaneously.; Download press release (PDF)
Karia Paukkeri named new CEO of Licentia: Feb 29, 2008—Licentia Ltd is the leading Finnish technology transfer company in the field of life sciences. Licentia commercialises inventions by licensing or selling IPR rights and in addition by building new start-up companies.; Download press release (PDF)
Innomedica establishes an office at London BioScience Innovation Centre: Jan 18, 2008; Download press release (PDF)
EC/EMEA has granted an Orphan Drug Designation for Traumakine: Dec 4, 2007—Traumakine has become the most fast progressing drug candidate within Faron Pharmaceuticals pipeline.; Download press release (PDF)
Ipsat Therapies Announces Positive Top-line Data from Phase IIb Study: Oct 25, 2007—Ipsat P1A phase IIb study met both primary endpoints.; Download press release (PDF)
Ipsat Therapies commences patient recruitment in Phase IIb clinical trial using its lead product P1A: Dec 4, 2006; Download press release (PDF)
Bio Fund exits succesfully Ark Therapeutics: Nov 10, 2006—Bio Fund Management Oy Ltd announces that it has sold all shares of Ark Therapeutics Group Plc., a London, UK, and Kuopio, Finland based biopharmaceutical company.; Download press release (PDF)
CTT Cancer Targeting Technologies Ltd. and Karyon Ltd. announce merger intention.: Oct 27, 2006; Download press release (PDF)
Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson’s Disease: Sep 5, 2006—Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, and Juvantia Pharma, a Finnish biotechnology company, announced today that they have entered into a strategic collaboration to advance the development of Juvantia’s fipamezole (JP-1730) for the treatment of Dyskinesia in Parkinson’s Disease (DPD) patients.; Download press release (PDF)
Nanogen announces type II diabetes research collaboration: May 17, 2006—Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, has announced a collaboration agreement with Oy Jurilab, Ltd., the Finnish genomics company. The collaboration is designed to identify and validate new prognostic markers for type II diabetes.; Download press release (PDF)
FibroGen Licenses Oral HIF-PH Inhibitors to Astellas for the Treatment of Anemia in Europe and Other Regions: May 5, 2006; Download press release (DOC)
DrugMEt Pharmacogenetics Product Achieves CE Mark for IVD Use: May 4, 2006—Jurilab, a privately-held Finnish biotechnology company, and Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that the European CE Mark for IVD (in vitro diagnostic) use has been achieved for the DrugMEt® pharmacogenetic test.; Download press release (DOC)
ETLA's book "Sustainable Biotechnology Development - New insights into Finland": Mar 31, 2006—Etlas's book analyses the features of the Finnish biotechnology industry from three complementary perspectives as a basis for a strategic sustainable biotechnology development framework: 1) How do the company leaders see the future of the industry? 2) How do the companies valuate their intellectual property rights? 3) How does the regional resource allocation reflect the prosperity of the industry?; Download press release (PDF)
New CEO in Ipsat Therapies: Feb 13, 2006—Ipsat Therapies announces the appointment of Nora Kaarela as Chief Executive Officer.; Download press release (PDF)
Galilaeus and Alpharma Announce Research Collaboration Deal: Jan 24, 2006—Under the Agreement, Galilaeus will leverage its extensive genetic engineering know-how to improve a bacterium strain used in the production of an active pharmaceutical ingredient.; Download press release (DOC)
Ipsat Therapies Completes € 3M Financing Round and Strenghtens Board of Directors: Jan 24, 2006; Download press release (PDF)
New CEO in CTT: Nov 25, 2005—Mr. Jari-Matti Mehto (M.Sc.) has been appointed as the CEO of the CTT Cancer Targeting Technologies Ltd on October 19, 2005.; Download press release (DOC)
CTT enters into R&D agreement with GE Healthcare: Oct 14, 2005—CTT Cancer Targeting Technologies Ltd. and GE Healthcare announced that they have entered into a research agreement in the area of targeted medical imaging.; Download press release (DOC)
Vivoxid Ltd closed EUR 5 million financing round: Sep 7, 2005—The financing round was led by Sentica Partners Oy. Other two major investors were Varma Mutual Pension Insurance Company and Sitra. Number of private persons and companies also participated.; Download press release (DOC)
Medipolis GMP announces cooperation agreement with Scil Proteins and Evolutec: Jun 10, 2005; Download press release (PDF)
Ipsat Therapies announces positive phase II results: Apr 5, 2005—Ipsat Therapies, a Finnish biopharmaceutical company with a novel approach to fighting hospital acquired infections and antibiotic resistance, today announced positive Phase IIa clinical trial data for its lead product, P1A. The product is designed to inactivate beta-lactam antibiotics in the lower intestinal tract, post bloodstream absorption.; Download press release (PDF)
Ipsat Therapies Completes EUR 7 million Financing Round and Strengthens Board of Directors: Apr 4, 2005—Ipsat Therapies, a Finnish biopharmaceutical company with a novel approach to fighting hospital acquired infections and antibiotic resistance, today announced it closed a EUR 7 million private placement bringing the total amount raised since inception to more than EUR 19 million.; Download press release (DOC)
Ark Grants Licence to Boehringer Ingelheim for Access to Key Technology: Apr 1, 2005—Ark Therapeutics Group plc today announces that it has signed an agreement with the German pharmaceutical company, Boehringer Ingelheim International GmbH, granting Boehringer Ingelheim exclusive rights to Ark’s intellectual property in relation to certain Boehringer Ingelheim therapies affecting the renin-angiotensin system.; Download press release (PDF)